Business

Pharma Executive Faces Regulatory Scrutiny

Updated 2026-10-13 15:25 UTC 1 source Negative

Martin Shkreli, the controversial pharmaceutical executive, is facing new regulatory challenges for his stock market commentary. Banned from trading, he continues to influence biopharma stocks.

Coverage timeline — 1 article

MarketWatch

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so.

2026-10-13 15:17 UTC